ReviewCancer letters2013
Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.
Review in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition.iScience · 2025Article
- Review
- Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities.Cancers · 2022Review
- Review
- LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma.Communications biology · 2021Article
- Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Extracellular acidosis differentiates pancreatitis and pancreatic cancer in mouse models using acidoCEST MRI.Neoplasia (New York, N.Y.) · 2019Article
- Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice.The Prostate · 2019Article
- Translational molecular imaging in exocrine pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2018Review
- Review
- Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.International journal of nanomedicine · 2018Article
- Targeting of the P2X7 receptor in pancreatic cancer and stellate cells.International journal of cancer · 2016Article
- Ultrasound imaging of splenomegaly as a proxy to monitor colon tumor development in Apc(min716/+) mice.Cancer medicine · 2016Article
- Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Targeting pancreatic ductal adenocarcinoma acidic microenvironment.Scientific reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.